ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Minnesota's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1992
Meetings & Education
Allied Health Professionals Award
State Society Education Series
MSCO 2020 Fall Conference Highlights
Patient Advocacy Organizations
State & Federal Resources
Financial Advocacy & Patient Assistance
Find A Clinical Trial
National Professional Organizations
Off-Label Use Literature
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Approves Pembrolizumab for Advanced Cervical Cancer
On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck and Co. Inc.) for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
Read the full FDA press release here.